AusBiotech suggests improvements to Innovation Patent system

29 September 2015

Trade group AusBiotech revealed today that it has made a submission to IP Australia’s consultation on improvements to the Innovation Patent system and the Advisory Council on Intellectual Property’s (ACIP) recommendation to abolish the system.

AusBiotech said it does not support the ACIP recommendation that the Innovation Patent system be abolished, but would instead support changes that would improve the Innovation Patent system in three key areas: raising the innovation threshold; requiring examination prior to grant; and setting an examination deadline. The submission recommended that:

Australia should retain a second-tier or lower-innovation-threshold patent system.
With appropriate modification, the Innovation Patent system can meet the needs of Australian innovators - particularly, but not limited to those of small and medium enterprises.
The threshold for an innovative step of an Innovation Patent should be raised.
Unexamined Innovation Patent applications should remain pending until an examination has been completed and the application accepted.
All Innovation Patents should be examined within a defined period. Three years is considered to be an appropriate maximum time for examination.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK